CCS platform saves more than $10M

DALLAS – CCS has saved more than $10 million in taxpayer dollars through the use of PropheSee, its predictive analytics platform, according to a new study. 

The company identified more than 14,400 Medicare patients at risk of lapsing on their continuous glucose monitoring therapy and segmented them into defined personas based on patient-specific clinical, socioeconomic and behavioral data. It then designed and deployed customized interventions to effect lasting behavior change, leading to millions of taxpayer dollars being saved in unused CGM devices and unnecessary care for this high-cost, high-risk population. 

“To combat the growing diabetes epidemic, we must focus on improving patient adherence and recognizing providers like CCS as essential members of the care ecosystem,” said Tony Vahedian, CEO of CCS. “As a specialized care provider, CCS has proven it can deliver vital diabetes interventions directly to the patient, improving outcomes and reducing costs for high-risk populations while saving taxpayers millions.” 

PropheSee, launched in June 2024, was awarded “Best Predictive Analytics Solution” as part of the MedTech Breakthrough Awards on May 8, 2025. The platform is an AI-powered predictive and intervention platform that actively identifies patients most at risk of stopping use of their CGM within 30 days with 85% accuracy and deploys highly personalized interventions to keep these patients on track. 

The study also found: 

• Adherence improved 46% when patients received messages aligned with provider trust. 

• Rural patients showed a 30% adherence boost when reminded of at-home support options. 

Related: CCS sees AI tool as next step in diabetes care evolution